Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study
JACC Cardiovascular Interventions, 07/17/2012Alexopoulos D et al.
In patients with acute coronary syndrome (ACS) exhibiting high on–treatment platelet reactivity (HTPR) while on clopidogrel 24 h post–PCI, ticagrelor produces a significantly higher platelet inhibition compared with prasugrel.
In a prospective, single–center, single–blind study, 44 (of 139 screened, 31.7%) ACS patients with HTPR while on clopidogrel 24 h post–PCI were randomized to either ticagrelor 90 mg twice daily or prasugrel 10 mg once daily for 15 days with a crossover directly to the alternate treatment for another 15 days.
HTPR was defined as platelet reactivity units (PRU) ≥235 as assessed by the VerifyNow P2Y12 function assay.
The primary endpoint of platelet reactivity at the end of the 2 treatment periods was lower for ticagrelor (32.9 PRU, 95% confidence interval [CI]: 18.7 to 47.2) compared with prasugrel (101.3 PRU, 95% CI: 86.8 to 115.7) with a least squares mean difference of –68.3 PRU (95% CI: –88.6 to –48.1; p < 0.001).
The secondary endpoint of HTPR rate was 0% for ticagrelor and 2.4% for prasugrel (1 of 42, p = 0.5).
No patient exhibited a major bleeding event at either treatment group.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.